Jump to content

Ritlecitinib: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
more ids
Line 123: Line 123:
[[Category:Breakthrough therapy]]
[[Category:Breakthrough therapy]]
[[Category:Non-receptor tyrosine kinase inhibitors]]
[[Category:Non-receptor tyrosine kinase inhibitors]]
[[Category:Pyrrolopyrimidines]]




Revision as of 01:03, 26 June 2023

Ritlecitinib
Clinical data
Trade namesLitfulo
Other namesPF-06651600
License data
Routes of
administration		By mouth
ATC code
  • None
Legal status
Legal status
Identifiers
  • 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC15H19N5O
Molar mass285.351 g·mol−1
3D model (JSmol)
  • C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=C3C=CNC3=NC=N2
  • InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1
  • Key:CBRJPFGIXUFMTM-WDEREUQCSA-N
  • Key:YOZLVAFWYLSRRN-VZXYPILPSA-N

Ritlecitinib, sold under the brand name Litfulo, is a medication used for the treatment of severe alopecia areata (hair loss).[1] Ritlecitinib is a kinase inhibitor which inhibits Janus kinase 3 and tyrosine kinase.[1][2][3]

Ritlecitinib was approved for medical use in the United States in June 2023.[1][4]

Medical uses

Ritlecitinib is indicated for the treatment of severe alopecia areata.[1]

References

  1. ^ a b c d e "LITFULOTM (ritlecitinib) capsules, for oral use". Pfizer, Inc.
  2. ^ "Ritlecitinib". Inxight Drugs. Retrieved 24 June 2023.
  3. ^ Ramírez-Marín HA, Tosti A (February 2022). "Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata". Drug Design, Development and Therapy. 16: 363–374. doi:10.2147/DDDT.S334727. PMC 8860347. PMID 35210753.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  4. ^ "FDA Approves Pfizer's Litfulo (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata" (Press release). Pfizer. 23 June 2023. Retrieved 24 June 2023 – via Business Wire.

Further reading

  • Guttman-Yassky E, Pavel AB, Diaz A, Zhang N, Del Duca E, Estrada Y, et al. (April 2022). "Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers". The Journal of Allergy and Clinical Immunology. 149 (4): 1318–1328. doi:10.1016/j.jaci.2021.10.036. PMID 34863853.
  • King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. (May 2023). "Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial". Lancet. 401 (10387). London, England: 1518–1529. doi:10.1016/S0140-6736(23)00222-2. PMID 37062298.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Ritlecitinib&oldid=1161944164"